Efficacy and tolerability of a low dose weekly paclitaxel, carboplatin and cetuximab (PCC) regimen for metastatic or unresectable head and neck squamous cell carcinomas

被引：0
|
作者：
Locke, Margaret [1 ,4 ]
Kohn, Nina [2 ]
Seetharamu, Nagashree [3 ]
机构：
[1] Zucker Sch Med Hofstra Northwell, Dept Internal Med, Manhasset, NY USA
[2] Northwell Hlth, Off Acad Affairs, Manhasset, NY USA
[3] Northwell Hlth, Monter Canc Ctr, Manhasset, NY USA
[4] 300 Community Dr, Manhasset, NY 11030 USA
来源：
CLINICAL OTOLARYNGOLOGY | 2023年 / 48卷 / 06期
关键词：
chemotoxicity; head and neck cancer; metastatic disease; unresectable head and neck cancer; CHEMOTHERAPY; RECURRENT;
D O I：
10.1111/coa.14091
中图分类号：
R76 [耳鼻咽喉科学];
学科分类号：
100213 ;
摘要：
引用
收藏
页码：915 / 919
页数：5
相关论文
共 50 条
  • [31] Clinical and immune effects of cetuximab and weekly low dose carboplatin and paclitaxel in head and neck cancer patients with poor performance status.
    Bonomi, Marcelo Raul
    Klamer, Brett
    Ahmed, Tamjeed
    Ado, Safoa
    Kooshki, Mitra
    Das, Jishu
    Brock, Guy
    Pierre, Triozzi
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [32] Activity of weekly paclitaxel−cetuximab chemotherapy in unselected patients with recurrent/metastatic head and neck squamous cell carcinoma: prognostic factors
    I. Pajares Bernad
    J. Martínez Trufero
    L. Calera Urquizu
    R. A. Pazo Cid
    A. Cebollero de Miguel
    M. J. Agustin
    M. Lanzuela
    A. Antón
    Clinical and Translational Oncology, 2017, 19 : 769 - 776
  • [33] Weekly Versus Tri-Weekly Paclitaxel and Carboplatin in Combination with Cetuximab in Recurrent/Metastatic Head and Neck Cancer Patients: a Toxicity Analysis
    Geraghty, L.
    Hoffman, S.
    Schultz, T.
    Porter, K.
    Issa, M.
    Rupert, R.
    Bhateja, P.
    Old, M.
    Rocco, J. W.
    Blakaj, D. M.
    Bonomi, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 106 (05): : 1199 - 1199
  • [34] Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma
    Haddad, R. I.
    Massarelli, E.
    Lee, J. J.
    Lin, H. Y.
    Hutcheson, K.
    Lewis, J.
    Garden, A. S.
    Blumenschein, G. R.
    William, W. N.
    Pharaon, R. R.
    Tishler, R. B.
    Glisson, B. S.
    Pickering, C.
    Gold, K. A.
    Johnson, F. M.
    Rabinowits, G.
    Ginsberg, L. E.
    Williams, M. D.
    Myers, J.
    Kies, M. S.
    Papadimitrakopoulou, V.
    ANNALS OF ONCOLOGY, 2019, 30 (03) : 471 - 477
  • [35] Clinical efficacy and tolerability of continuous course reirradiation with concurrent weekly carboplatin-paclitaxel for locally recurrent, nonmetastatic squamous cell carcinoma of the head and neck (SCCHN).
    Marwaha, A.
    Choong, N. W.
    Firat, S.
    Schultz, C. J.
    Wang, D.
    Wong, S. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [36] A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
    Dunn, L. A.
    Fury, M. G.
    Xiao, H.
    Baxi, S. S.
    Sherman, E. J.
    Korte, S.
    Pfister, C.
    Haque, S.
    Katabi, N.
    Ho, A. L.
    Pfister, D. G.
    ANNALS OF ONCOLOGY, 2017, 28 (10) : 2533 - 2538
  • [37] WEEKLY REGIMEN OF PACLITAXEL-CARBOPLATIN-CETUXIMAB AS FIRST-LINE CHEMOTHERAPY IN PATIENTS WITH PLATINUM-RESISTANT RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF HEAD AND NECK (SSCHN): RESULTS OF A PHASE II STUDY
    Rozzi, A.
    Lenci, G.
    Corona, M.
    Nardoni, C.
    Restuccia, M. R.
    Falbo, T.
    Nappa, M.
    Costa, A. M.
    Spigone, B.
    Lanzetta, G.
    ANNALS OF ONCOLOGY, 2010, 21 : 323 - 323
  • [38] Simlukafusp a and cetuximab combination in patients with recurrent, unresectable or metastatic squamous cell carcinoma of the head and neck
    Hansen, A. R.
    Gomez-Roca, C. A.
    Lolkema, M. P.
    Verlingue, L.
    Italiano, A.
    Spicer, J.
    Steeghs, N.
    Bauman, J. E.
    Fayette, J.
    Niu, J.
    Prenen, H.
    Dejardin, D.
    Boetsch, C.
    Kraxner, A.
    Evers, S.
    Vardar, T.
    Keshelava, N.
    Teichgraber, V.
    Bonomi, M.
    ANNALS OF ONCOLOGY, 2021, 32 : S805 - S805
  • [39] A multicenter phase II trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck
    Enokida, Tomohiro
    Ogawa, Takenori
    Homma, Akihiro
    Okami, Kenji
    Minami, Shujiro
    Nakanome, Ayako
    Shimizu, Yasushi
    Maki, Daisuke
    Ueda, Yuri
    Fujisawa, Takao
    Motegi, Atsushi
    Ohkoshi, Akira
    Taguchi, Jun
    Ebisumoto, Koji
    Nomura, Shogo
    Okano, Susumu
    Tahara, Makoto
    CANCER MEDICINE, 2020, 9 (05): : 1671 - 1682
  • [40] Induction chemotherapy with cetuximab, carboplatin and paclitaxel for the treatment of locally advanced squamous cell carcinoma of the head and neck
    Bauman, Jessica
    Langer, Corey
    Quon, Harry
    Algazy, Kenneth
    Lin, Alexander
    Desai, Arati
    Mutale, Faith
    Weiss, Jared
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2013, 5 (04) : 1247 - 1253
12345